Head-to-head · free
Genmab vs Eli Lilly
GMAB vs LLY — return on capital, cash generation, margins and balance sheet side by side.
GMAB
1 / 5
measures where GMAB leads
LLY
4 / 5
measures where LLY leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | GMAB | LLY · FY2025 |
|---|---|---|
| Revenue | — | $65.2B |
| Net income | — | $20.6B |
| Revenue growth (yearly, multi-year) | — | 23.2% |
| Free cash flow | — | — |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | 10.1% | 36.1% |
| Return on equity | 17.5% | 101.4% |
| Gross margin | 93.6% | 83.0% |
| Operating margin | 33.6% | 45.6% |
| Net debt / EBITDA | 3.13x | 1.25x |
Figures are as reported by each company; latest fiscal year shown.
Where Eli Lilly's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free